three and six months ended March 31, 2018, the net loss included recurring charges of $1.0 million and $2.1 million, respectively, related to amortization expense of acquired intangible assets.  
 The Company reports the results of operations for Tec-Sem in the Brooks Semiconductor Solutions Group segment starting from the acquisition date. The revenues and net income from Tec-Sem included in the Company's consolidated results for the three months ended March 31, 2019 were $5.7 million and $0.9 million, respectively. The revenues and net income from Tec-Sem included in the Company's consolidated results for the six months ended March 31, 2019 were $15.1 million and $2.6 million, respectively. During the three months ended March 31, 2019, the net income included $0.9 million related to amortization expense of acquired intangible assets. During the six months ended March 31, 2019, the net income included $0.2 million related to the step-up in value of the acquired inventories and $1.8 million related to amortization expense of acquired intangible assets.  
 Amortization expense for intangible assets was $17.2 million and $11.1 million, respectively, during the six months ended March 31, 2019 and 2018.  
 The operating results of 4titude have been reflected in the results of operations for the Brooks Life Sciences segment from the date of the acquisition. During the three months ended March 31, 2019, revenue and net income from 4titude recognized in the Company’s results of operations were $4.7 million and $0.3 million, respectively. During the six months ended March 31, 2019, revenue and net loss from 4titude recognized in the Company’s results of operations were $8.5 million and $0.4 million, respectively. During the three months ended March 31, 2018, revenue and net loss from 4titude recognized in the Company’s results of operations were $4.3 million and less than $0.1 million, respectively. During the six months ended March 31, 2018, revenue and net loss from 4titude recognized in the Company’s results of operations were $7.8 million and $1.2 million, respectively. During the six months ended March 31, 2018, the net loss included non-recurring charges of $1.2 million related to the step-up in value of the acquired inventories. During the three and six months ended March 31, 2019, the net loss included recurring charges of $0.9 million and $1.9 million, respectively, related to amortization expense of acquired intangible assets. During the 
 The table above reflects revenue for the three and six months ended March 31, 2019 in accordance with ASC 606, while results for the three and six months ended March 31, 2018 have not been restated and are reported in accordance with the governing revenue recognition standards applicable to that period. Results for the three and six months ended March 31, 2019 were not significantly impacted by the adoption of ASC 606.  
 The semiconductor cryogenics business consists of the CTI pump business, Polycold chiller business, the related services business and the Company's 50% share in Ulvac Cryogenics, Inc., a joint venture based in Japan. The semiconductor cryogenics business was originally acquired by the Company in its 2005 merger with Helix Technology Corporation and is included in the Brooks Semiconductor Solutions Group segment as part of the segment.  
 The Brooks Life Sciences segment provides comprehensive life cycle sample management solutions to life science and bioscience customers including complete end-to-end “cold chain of custody” solutions and a variety of sample-based lab services such as genomic sequencing and synthesis to advance scientific research and support drug development. The segment’s product offerings include automated cold sample management systems for compound and biological sample storage, equipment for sample preparation and handling, consumables, and informatics that help customers manage samples throughout their research discovery and development work flows. The segment’s service offerings include sample storage, genomic sequencing, genomic synthesis, lab processing services, lab analysis, and other support services provided to a wide range of life science customers, including pharmaceutical companies, biotechnology companies, biobanks and research institutes.  
 Goodwill of $7.7 million largely reflects the potential synergies and expansion of technical capabilities to the Company's existing contamination control solutions business. The goodwill from this acquisition is reported within the Brooks Semiconductor Solutions Group segment and is not tax deductible.   
 During the three and six months ended March 31, 2018, the Company incurred $0.5 million and $1.0 million, respectively, in non-recurring transaction costs with respect to the 4titude acquisition, which were recorded in "Selling, general and administrative" expenses within the accompanying unaudited Consolidated Statements of Operations. There were no transaction costs related to the 4titude acquisition during the three and six months ended March 31, 2019.  
 The revenues and net loss from GENEWIZ recognized in the Company's consolidated results of operations were $32.8 million and $0.3 million, respectively for the three months ended March 31, 2019. The revenues and net income from GENEWIZ recognized in the Company’s consolidated results of operations were $49.3 million and $0.5 million, respectively for the reporting period since acquisition. During the three months ended March 31, 2019, and the period since acquisition, net income included $3.2 million and $4.8 million, respectively, related to amortization expense of acquired intangible assets. The Company incurred $3.8 million in transaction costs with respect to the GENEWIZ acquisition during fiscal year 2018. During the three and six months ended March 31, 2019, the Company incurred $0.1 million and $6.4 million, respectively, in transaction costs, which were recorded in "Selling, general and administrative" expenses within the accompanying unaudited Consolidated Statements of Operations.   
 The Brooks Semiconductor Solutions Group segment provides a variety of products, services and solutions that enable improved throughput and yield in controlled operating environments, as well as an extensive range of support services. The solutions include atmospheric and vacuum robots, robotic modules, tool automation systems, contamination control of wafer carrier front opening unified pods and reticle management. The support services include repair services, diagnostic support services, and installation services in support of the products, which enable the customers to maximize process tool uptime and productivity. This segment also provides end-user customers with spare parts and productivity enhancement upgrades to maximize tool productivity.   
 The weighted average grant date fair value of restricted stock units granted during the three months ended March 31, 2019 and 2018 was $29.73 and $25.41, respectively. The weighted average grant date fair value of restricted stock units granted during the six months ended March 31, 2019 and 2018 was $30.45 and $33.61, respectively. The fair value of restricted stock units vested during the three months ended March 31, 2019 and 2018 was $3.4 million and $0.1 million, respectively. The fair value of restricted stock units vested during the six months ended March 31, 2019 and 2018 was $31.1 million and $19.1 million, respectively. During the six months ended March 31, 2019 and 2018, the Company remitted $14.2 million and $6.3 million, respectively, collected from employees to satisfy their tax obligations as a result of share issuances. Such proceeds collected and remitted were insignificant during the three months ended March 31, 2019 and 2018.   
 Goodwill of $236.8 million largely reflects the potential synergies and expansion of the Company’s core technologies and offerings in the Life Sciences business. The goodwill from this acquisition is reported within the Brooks Life Sciences segment and is not tax deductible. During the three months ended March 31, 2019, a $0.3 million measurement period adjustment was recorded related to the working capital settlement which increased goodwill.    Research and development expenses were $14.1 million and $27.2 million, respectively, during the three and six months ended March 31, 2019 as compared to $11.3 million and $22.8 million, respectively, during the corresponding periods of the prior fiscal year. The increase of $2.8 million during the second quarter of fiscal year 2019 as compared to the corresponding period of fiscal year 2018 reflects higher expense of $1.8 million within the Brooks Life Sciences segment and $1.0 million within the Brooks Semiconductor Solutions Group segment. The increase of $4.4 million during the first half of fiscal year 2019 reflects higher expense of $2.5 million within the Brooks Life Sciences segment and $1.9 million within the Brooks Semiconductor Solutions Group segment. Higher expenses in both periods were primarily attributable to new acquisitions and higher employee related costs.   
 Amortization expense related primarily to customer relationships was $6.6 million and $12.4 million, respectively, during the three and six months ended March 31, 2019 as compared to $4.6 million and $9.2 million, respectively, during the corresponding periods of the prior fiscal year. Merger-related costs were $0.0 million and $6.4 million, respectively, during the three and six months ended March 31, 2019 as compared to $1.6 million and $2.3 million, respectively, during the corresponding periods of the prior fiscal year. The increases in amortization expense and merger costs during 2019 are due to the acquisition of GENEWIZ.  
 We reported gross margins of 40.6% for the three months ended March 31, 2019 compared to 39.7% for the corresponding period of the prior fiscal year. Gross margin increased in the Brooks Semiconductor Solutions Group segment by 0.7 percentage points and in the Brooks Life Sciences segment by 1.4 percentage points in the 2019 period over the 2018 period. We reported gross margins of 40.4% for the six months ended March 31, 2019 compared to 38.9% for the corresponding period of the prior fiscal year. Gross margin increased in the Brooks Semiconductor Solutions Group segment by 0.5 percentage points and in the Brooks Life Sciences segment by 3.7 percentage points in the 2019 period over the 2018 period. Cost of revenue for the three and six months ended March 31, 2019 included $2.8 million and $4.8 million, respectively, of charges for amortization related to completed technology as compared to $1.0 million and $1.9 million, respectively, during the corresponding periods of the prior fiscal year. Cost of revenue for the three and six months ended March 31, 2019 also included $0.0 million and $0.2 million, respectively, of charges related to the inventory step-up in purchase accounting, as compared to $0.0 million and $1.2 million, respectively, during the corresponding periods of the prior fiscal year. Excluding the purchasing accounting impact related to inventory step-up and the amortization of completed technology, gross margins expanded 1.6 percentage points and 1.7 percentage points, respectively, during the three and six months ended March 31, 2019 as compared to the corresponding periods of the prior fiscal year. The difference in reported gross margin due to the adoption of the new revenue recognition standard was a net decrease in gross profit of $0.7 million and $0.8 million during three and six months ended March 31, 2019, respectively.   
 Results of Operations - Revenue for the three months ended March 31, 2019 increased to $198.4 million, or by 26%, as compared to the corresponding period of the prior fiscal year. Gross margin was 40.6% for the three months ended March 31, 2019 as compared to 39.7% for the corresponding period of the prior fiscal year, an increase of $18.1 million. Operating expenses were $66.8 million during the three months ended March 31, 2019 as compared to $52.1 million during the corresponding period of the prior fiscal year, an increase of $14.8 million. Operating income was $13.7 million during the second quarter of fiscal year 2019 as compared to $10.3 million for the corresponding period of the prior fiscal year. Loss from continuing operations was $2.8 million for the second quarter of fiscal year 2019, which includes a $9.1 million loss on extinguishment of debt. This compares to income from continuing operations of $62.5 million for the corresponding period of the prior fiscal year, which included the reversal of the valuation allowance reserve against U.S. deferred income tax assets of $58.0 million.   
 Results of Operations - Revenue for the six months ended March 31, 2019 increased to $377.8 million, or by 26%, as compared to the corresponding period of the prior fiscal year. Gross margin was 40.4% for the six months ended March 31, 2019 as compared to 38.9% for the corresponding period of the prior fiscal year, an increase of $36.0 million. Operating expenses were $133.6 million during the six months ended March 31, 2019 as compared to $101.4 million during the corresponding period of the prior fiscal year, an increase of $32.2 million. Operating income was $19.0 million during the six months ended March 31, 2019 as compared to $15.2 million for the corresponding period of the prior fiscal year. Income from continuing operations was $3.4 million for the six months ended March 31, 2019 as compared to $64.1 million for the corresponding period of the prior fiscal year. The decrease of $60.7 million was primarily attributable to the reversal of the valuation allowance reserve against U.S. deferred income tax benefits of $58.0 million in the prior fiscal year, and a $9.1 million loss on extinguishment of debt in the 2019 period.   